Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
Executive Summary
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
You may also be interested in...
Optellum Joins J&J’s Lung Cancer Initiative
Optellum’s Virtual Nodule Clinic artificial intelligence technology will be part of Johnson & Johnson’s Lung Cancer Initiative, an ongoing research program intended to improve lung cancer survival rates through early intervention and prevention.
Finance Watch: Nkarta, Passage Bio Raise Venture Capital Mega-Rounds
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.